The Experts below are selected from a list of 426 Experts worldwide ranked by ideXlab platform
Admir Hadzic - One of the best experts on this subject based on the ideXlab platform.
-
Cervical plexus and greater occipital Nerve blocks: controversies and technique update.
2019Co-Authors: Roy A. Greengrass, Samer Narouze, Thomas Fichtner Bendtsen, Admir HadzicAbstract:The cervical plexus originates from the anterior rami of the C1–C4 cervical spinal Nerves.[1 2][1] The anterior ramus of C1 (the Suboccipital Nerve) is a motor Nerve not blocked as part of any described technique of cervical plexus blockade. Thus, a cervical plexus block is properly defined as a
John F Rothrock - One of the best experts on this subject based on the ideXlab platform.
-
Suboccipital Nerve blocks for suppression of chronic migraine safety efficacy and predictors of outcome
2010Co-Authors: Silvia Weibelt, Diane Andressrothrock, Wesley King, John F RothrockAbstract:(Headache 2010;50:1041-1044) Background.— Approximately 1 in 50 Americans is afflicted by chronic migraine (CM). Many patients with CM describe cervicogenic headache. Options for treating CM effectively are at present quite limited. Objective.— To determine the safety and efficacy of occipital Nerve blocks (ONBs) used to treat cervicogenic chronic migraine (CCM) and to identify variables predictive of a positive treatment response. Methods.— Using a uniform dose and injection paradigm, we performed ONBs consecutively on a series of patients presenting with CCM. Patients were stratified according to specific findings found to be present or absent on physical examination. A positive treatment outcome was defined as a 50% or greater reduction in headache days per month over the 30 days following treatment relative to the 30-day pre-treatment baseline. We used a 5-point Likert scale as one of the secondary outcome variables. Results.— We treated 150 consecutive patients with unilateral (37) or bilateral (113) ONBs. At the 1-month follow-up visit 78 (52%) exhibited evidence of a positive treatment response according to the primary outcome variable, and 90 (60%) reported their headache disorder to be “better” (44; 29%) or “much better” (46; 30%). A total of 8 (5%) patients reported adverse events within the ensuing 72 hours, and 3 (2%) experienced adverse events that reversed spontaneously but required emergent evaluation and management. Conclusion.— For suppression of CCM, ONBs may offer an attractive alternative to orally administered prophylactic therapy.
Roy A. Greengrass - One of the best experts on this subject based on the ideXlab platform.
-
Cervical plexus and greater occipital Nerve blocks: controversies and technique update.
2019Co-Authors: Roy A. Greengrass, Samer Narouze, Thomas Fichtner Bendtsen, Admir HadzicAbstract:The cervical plexus originates from the anterior rami of the C1–C4 cervical spinal Nerves.[1 2][1] The anterior ramus of C1 (the Suboccipital Nerve) is a motor Nerve not blocked as part of any described technique of cervical plexus blockade. Thus, a cervical plexus block is properly defined as a
Todd D Rozen - One of the best experts on this subject based on the ideXlab platform.
-
high volume anesthetic Suboccipital Nerve blocks for treatment refractory chronic cluster headache with long term efficacy data an observational case series study
2019Co-Authors: Todd D RozenAbstract:Objective To determine the efficacy of high-volume anesthetic Suboccipital Nerve blocks (HVSON) for chronic cluster headache (CCH) and to define consistency of response over long-term use. Background There are studies showing efficacy of greater occipital and Suboccipital Nerve block injections for CCH and also their possible use as a preventive treatment modality. There are scant data about the long-term efficacy of repetitive greater occipital and Suboccipital Nerve injections in CCH. HVSON has not been studied for CH. Methods This was an open label, observational, case series study. Patients with CCH seen at a dedicated headache clinic over a 7-year time period and injected on at least 2 separate occasions were used for analysis. All were deemed medicinal treatment refractory. HVSON consisted of 9 mL 1% lidocaine and 1 mL triamcinolone 40 mg/mL injected on the side of CH. Results Ten CCH patients were retrospectively studied. Range of mean average response to HVSON (all patients had complete pain freedom) was 1.5-31 weeks (longest: 44 weeks in 2 patients). Only one patient did not respond; 2 patients had 1.5-2 weeks of response; the remainder had at least 4 weeks of response. The mean average duration of effect was 10.3 weeks in the responders. Five patients were injected serially for 2-4 years (30x, 17x, 15x, 10x and 3x, respectively) with a consistent response of 6 weeks, 4 weeks, 12 weeks, 4 weeks, and 31 weeks, respectively, after each injection. Response duration was very reliable per individual patient. All 5 patients felt HVSON was effective as a preventive treatment. Smoking history did not appear to alter treatment response (8/10 were chronic current smokers and 7/8 responded to HVSON). The one patient who received the most injections developed avascular necrosis of the hip; the remainder of the subjects had no adverse events. Conclusion HVSON from this open label study appears to be effective in the preventive treatment of medicinal refractory CCH and shows consistent response over long-term use with high rates of pain freedom.
Samer Narouze - One of the best experts on this subject based on the ideXlab platform.
-
Cervical plexus and greater occipital Nerve blocks: controversies and technique update.
2019Co-Authors: Roy A. Greengrass, Samer Narouze, Thomas Fichtner Bendtsen, Admir HadzicAbstract:The cervical plexus originates from the anterior rami of the C1–C4 cervical spinal Nerves.[1 2][1] The anterior ramus of C1 (the Suboccipital Nerve) is a motor Nerve not blocked as part of any described technique of cervical plexus blockade. Thus, a cervical plexus block is properly defined as a
